DLBCL Prognosis Using BCL6 VEGF CD68 Biomarker Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the clinical response of diffuse large B-cell lymphoma (DLBCL) patients to therapy are inadequate, as they fail to account for the heterogeneity of the disease, leading to variable treatment outcomes despite the use of prognostic indices like IPI, and there is a need for more standardized biologic markers for predicting outcomes and defining therapies.
Innovation Solution
An in vitro method involving quantitative immunofluorescence to determine the levels of BCL6, VEGF, and CD68 proteins in patient samples, where high levels indicate poor prognosis and low levels indicate good prognosis, allowing for the selection of patients for individualized therapy based on biomarker expression profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional prognostic indices like IPI are used to predict therapy response in DLBCL patients, then the method is simple and widely applicable, but the prediction accuracy is insufficient due to disease heterogeneity
Solution Approach 1:
The patent segments DLBCL into distinct molecular subtypes (GCB-type and non-GCB-type) based on gene expression profiles, allowing for more precise prognostic prediction within heterogeneous patient populations. This segmentation enables tailored prognostic assessment that accounts for biological differences between subtypes.
Solution Approach 2:
The patent transitions from traditional clinical parameters (IPI) to molecular parameters (gene expression profiles, specific marker proteins) to improve prognostic accuracy. By changing the measurement parameters from clinical to molecular level, the patent achieves better prediction while maintaining practical applicability through standardized profiling methods.
2Reliability
If multiple biomarkers are analyzed to improve prognosis prediction, then prediction accuracy improves, but the complexity of the assessment method increases
Solution Approach 1:
The patent combines multiple biomarkers (BCL6, VEGF, CD68) into an integrated assessment framework that evaluates their combined prognostic value. By merging these markers into a unified analysis approach, the patent achieves more reliable prognosis while managing complexity through systematic evaluation protocols.
Solution Approach 2:
The patent develops a multi-functional prognostic system that can assess multiple biomarkers using standardized methodologies applicable across different patient cohorts. This universal approach allows the same assessment framework to evaluate various biomarker combinations, improving reliability without proportionally increasing complexity.
3Productivity
If personalized therapy selection is implemented based on biomarker profiles, then treatment effectiveness improves, but the complexity of patient selection and management increases
Solution Approach 1:
The patent performs preliminary molecular profiling of patient samples to identify biomarker patterns before finalizing therapy selection. This preliminary assessment establishes a foundation for personalized treatment decisions, improving effectiveness while managing selection complexity through structured evaluation protocols.
Solution Approach 2:
The patent implements feedback mechanisms where biomarker results inform therapy selection, and treatment response is monitored and fed back into the decision-making process. This iterative approach improves treatment effectiveness by adapting to individual patient responses while managing complexity through systematic feedback loops.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a more accurate prognosis and treatment selection by correlating biomarker levels with clinical outcomes, improving overall survival and response to CHOP-R therapy in DLBCL patients, and can be used in combination with clinical parameters like IPI and age to stratify patient risk.
Implementation Method 1
determining in a sample from said patient the level of BCL6 protein by quantitative immunofluorescence
Data Source
Figure 1A~1F
Figure 2A~2C
Figure 3A~3C
AI summary
The method for prognosis of a patient suffering from diffuse large B-cell lymphoma (DLBCL) comprises determining in a sample from said patient the level of at least one biomarker selected from the group consisting of VEGF, BCL6, CD68, CD20, and combinations thereof.